Literature DB >> 12228273

Influence of intravenous anesthesia on mucosal and systemic antibody responses to nasal vaccines.

Libuse Janakova1, Hilde Bakke, Inger Lise Haugen, Aud K H Berstad, E Arne Høiby, Ingeborg S Aaberge, Bjørn Haneberg.   

Abstract

Inhalation of antigens may stimulate the immune system by way of the upper as well as the lower airways. We have shown that at least 1,000 times more live pneumococci were recovered from pulmonary tissue after being presented as drops of a liquid suspension onto the nares of anesthetized mice compared to the number of bacteria recovered from animals that were not anesthetized in the course of the challenge. Mice that were similarly immunized intranasally by inhalation of three different nonreplicating particulate vaccine formulations, i.e., a meningococcal outer membrane vesicle (OMV) vaccine, a formalin-inactivated whole-virus influenza (INV) vaccine, and the INV vaccine with OMVs as a mucosal adjuvant, during general intravenous anesthesia developed concentrations of vaccine-specific serum immunoglobulin G (IgG) antibodies that were four to nine times higher than in mice that were fully awake during immunizations. The concentrations of IgA antibodies in serum were also higher in anesthetized than in nonanesthetized mice and correlated positively with the corresponding levels of serum IgG antibodies in the anesthetized but not in the nonanesthetized mice. In saliva and feces, however, the concentrations of IgA antibodies were equally high whether or not the animals were dormant during immunizations. The results indicate that intrapulmonary antigen presentation, as a part of an intranasal immunization strategy, is of importance for systemic but not for mucosal antibody responses. A major portion of IgA antibodies in serum may thus be derived from nonmucosal sites.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12228273      PMCID: PMC128324          DOI: 10.1128/IAI.70.10.5479-5484.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers.

Authors:  J J Drabick; B L Brandt; E E Moran; N B Saunders; D R Shoemaker; W D Zollinger
Journal:  Vaccine       Date:  1999-08-20       Impact factor: 3.641

Review 2.  Structure and function of bronchus-associated lymphoid tissue (BALT).

Authors:  T Sminia; G J van der Brugge-Gamelkoorn; S H Jeurissen
Journal:  Crit Rev Immunol       Date:  1989       Impact factor: 2.214

Review 3.  Is BALT a major component of the human lung immune system?

Authors:  R Pabst
Journal:  Immunol Today       Date:  1992-04

4.  Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey.

Authors:  E A Høiby; E Rosenqvist; L O Frøholm; G Bjune; B Feiring; H Nøkleby; E Rønnild
Journal:  NIPH Ann       Date:  1991-12

Review 5.  The role of nasopharyngeal lymphoid tissue.

Authors:  C F Kuper; P J Koornstra; D M Hameleers; J Biewenga; B J Spit; A M Duijvestijn; P J van Breda Vriesman; T Sminia
Journal:  Immunol Today       Date:  1992-06

6.  Intranasal immunization with proteoliposomes protects against influenza.

Authors:  N el Guink; R M Kris; G Goodman-Snitkoff; P A Small; R J Mannino
Journal:  Vaccine       Date:  1989-04       Impact factor: 3.641

7.  Virulence of Streptococcus pneumoniae in mice: a standardized method for preparation and frozen storage of the experimental bacterial inoculum.

Authors:  I S Aaberge; J Eng; G Lermark; M Løvik
Journal:  Microb Pathog       Date:  1995-02       Impact factor: 3.738

8.  Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces.

Authors:  B Haneberg; D Kendall; H M Amerongen; F M Apter; J P Kraehenbuhl; M R Neutra
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

9.  Outcome of influenza infection: effect of site of initial infection and heterotypic immunity.

Authors:  R A Yetter; S Lehrer; R Ramphal; P A Small
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

10.  Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease.

Authors:  J H Fredriksen; E Rosenqvist; E Wedege; K Bryn; G Bjune; L O Frøholm; A K Lindbak; B Møgster; E Namork; U Rye
Journal:  NIPH Ann       Date:  1991-12
View more
  4 in total

1.  Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Authors:  William M Gwinn; Shaun M Kirwan; Sheena H Wang; Kathleen A Ashcraft; Neil L Sparks; Catherine R Doil; Tom G Tlusty; Leslie S Casey; Susan K Hollingshead; David E Briles; Richard S Dondero; Anthony J Hickey; W Michael Foster; Herman F Staats
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

2.  Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles.

Authors:  Brian R Sloat; Zhengrong Cui
Journal:  Pharm Res       Date:  2006-01-01       Impact factor: 4.200

Review 3.  Cytokines: the future of intranasal vaccine adjuvants.

Authors:  Afton L Thompson; Herman F Staats
Journal:  Clin Dev Immunol       Date:  2011-07-31

4.  Intranasal immunization strategy to impede pilin-mediated binding of Pseudomonas aeruginosa to airway epithelial cells.

Authors:  Jennifer C Hsieh; Doris M Tham; Weijun Feng; Fan Huang; Selamawit Embaie; Keyi Liu; Deborah Dean; Ralf Hertle; David J Fitzgerald; Randall J Mrsny
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.609

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.